Molecular epidemiology and susceptibility profiles of clostridium difficile in New Zealand, 2009

New Zealand Medical Journal

Volumn 124, Issue 1332, 2011, Pages 45-51

  Roberts, Sally ^a   Heffernan, Helen ^b   Anbuky, Nadia Al ^c   Pope, Christopher ^b   Paviour, Susan ^c   Camp, Tracey ^c   Swager, Terri ^c  

^a Auckland District Health Board ^*  (New Zealand)

^b Nosocomial Infections Laboratory   (New Zealand)

^c AUCKLAND DISTRICT HEALTH BOARD   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; MEROPENEM; METRONIDAZOLE; MOXIFLOXACIN; PENICILLIN G; PIPERACILLIN; TAZOBACTAM; VANCOMYCIN;

ADULT; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CLOSTRIDIUM DIFFICILE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEW ZEALAND; NONHUMAN; POLYMERASE CHAIN REACTION; RIBOTYPING;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; CLOSTRIDIUM DIFFICILE; CROSS INFECTION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; NEW ZEALAND; POLYMERASE CHAIN REACTION; POPULATION SURVEILLANCE; RIBOTYPING; VIRULENCE;

EID: 79955547159     PISSN: None     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Kuijper EJ, Coignard B, Tüll P on behalf of the ESCMID Study Group for Clostridium difficile, EU member States and the European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:S2-18.
2. Bignardi GE. Risk factors for Clostridium difficile infection. J Hosp Infect. 1998;40:1-15.
3. Thomas C, Stevenson M, Riley TV. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother. 2003;51:1339-50.
4. McDonald LC, Killgove GE, Thompson A, et al. An epidemic, toxin gene-variant strain of Clostridium difficile. NEJM. 2005;353:2433-41.
5. Oughton MT, Miller MA. Clinical and epidemiological aspects of Clostridium difficile. Clin Microbiol Newslett. 2008;30:87-95.
6. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. NEJM. 2008;359:1932-40.
7. Riley TV, Thean S, Hool G, Golledge CL. First Australian isolation of epidemic Clostridium difficile PCR ribotype 027. Med J Aust. 2009;190:706-8.
8. Wallace L. Identification of a hypervirulent strain of Clostridium difficile. Melbourne, Australia: Victorian Government Health Information; 2010 May. Hospital Circular 15/2010.
9. Clinical and Laboratory Standards Institute. Methods for antimicrobial susceptibility testing for anaerobic bacteria; approved standard - seventh edition. Wayne (PA): Clinical and Laboratory Standards Institute; 2007. Document M11-A7.
10. Hall V. PCR ribotyping of Clostridium difficile. Version ARUSOP 039.1. Cardiff: Anaerobe Reference Unit, Microbiology Service, National Public Health Service for Wales; 2007 Sep.
11. Persson S, Torpdahl M, Olsen KEP. New multiplex PCR method for the detection of Clostridium difficile toxin A (tcdA) and toxin B (tcdB) and the binary toxin (cdtA/cdtB) genes applied to a Danish strain collection. Clin Microbiol Infect. 2008;14:1057-64.
12. Curry SR, Marsh JW, Muto CA, et al. tcdC genotypes associated with severe tcdC truncation in an epidemic clone and other strains of Clostridium difficile. J Clin Microbiol. 2007;45:215-21.
13. Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis. 2008;47:1162-70
14. Mulvey MR, Boyd DA, Gravel D, et al Hypervirulent Clostridium difficile strains in hospitalised patients, Canada. Emerg Infect Dis. 2010;16:678-81.
15. Burns K, Morris-Downes M, Fawley WN, et al. Infection due to C. difficile ribotype 078: first report of cases in the Republic of Ireland. J Hosp Infect. 2010;75:287-91.
16. Keel K, Brazier JS, Post KW, et al. Prevalence of PCR ribotypes among Clostridium difficile isolates from pigs, calves and other species. J Clin Microbiol. 2007;45:1963-4.
17. Goorhuis A, Debast SB, van Leengeod LAMG, et al. Clostridium diffiicile PCR ribotype 078: an emerging strain in humans and pigs. J Clin Microbiol. 2008;46:1157-8.
18. Leroi MJ, Siarakas S, Gottlieb T. E Test susceptibility testing of nosocomial Clostridium difficile isolates against metronidazole, vancomycin, fusidic acid and the novel agents moxifloxacin, gatifloxacin and linezolid. Eur J Clin Microbiol Infect Dis. 2002;21:72-4.
19. John R, Brazier JS. Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect. 2005;61:11-4.
20. Hecht DW, Galang MA, Sambol SP, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother. 2007;51:2716-9.
21. Tang-Feldman YJ, Henderson JP, Ackermann G, et al. Prevalence of the ermB gene in Clostridium difficile strains isolated at a university teaching hospital from 1987 through 1998. Clin Infect Dis. 2005;40:1537-40.
22. Bourgault A, Lamothe F, Loo VG, et al. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Québec, Canada. Antimicrob Agents Chemother. 2006;50:3473-5.
23. Clements ACA, Magalh[abreve]es RJS, Tatem AJ, et al. Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis. 2010;10:395-404.